C
Claritas Genomics
Providing the highest quality testing services for diagnosis of pediatric disorders
About Claritas Genomics
Claritas Genomics is a genetic diagnostic laboratory specializing in pediatric disorders. Originating from the in-house genetic testing lab at Boston Hospital, Claritas was launched as a standalone entity in February 2013. The company serves healthcare providers, particularly pediatric hospitals, by offering comprehensive genetic testing services. Claritas operates in the genomics market, focusing on providing accurate and timely diagnostic information to improve patient care. The business model revolves around offering a range of genetic tests, including the Pediatric Neurology Exome and the Nephrotic Syndrome Panel, which are designed to diagnose complex pediatric conditions. Revenue is generated through the sale of these diagnostic tests and associated services, such as clinical reporting and expert consultations. The company also engages in research services, offering Ion Exome Sequencing to researchers. Claritas is committed to advancing the field of genomics through educational resources and partnerships with healthcare providers.
Source: Dealroom company dataAt a glance
- Founded
- 2013
- Headquarters
- Cambridge, United States
- Sector
- Health
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
- CCCerner Capital
Genuity Science
Cerner (Formerly PGI & Associates)
Cincinnati Children’s Hospital Medical Center
Children’s Hospital Boston
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Claritas Genomics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Claritas Genomics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.